Express News | BriaCell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of a $5 Million Registered Direct Offering of 2,402,935 Shares and Warrants at a Combined Purchase Price of $2 per Share

Benzinga12:36 ET

BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble

BriaCell Therapeutics (BCTX) shares were slumping about 10% in recent US trading on Wednesday after the immunotherapy company said it priced a private placement of slightly more than 2.4 million of it

MT NewswiresMay 15 11:36 ET

BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

Stockhouse May 15 08:00 ET

BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting

BriaCell Therapeutics (BCT.TO), which is developing immunotherapies to treat cancer, said it will make a presentation on the clinical data of the randomized Phase 2 study evaluating Bria-IMT in patien

MT NewswiresApr 24 09:00 ET

BriaCell Announces Oral and Poster Presentations at ASCO 2024

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell)

GlobeNewswireApr 24 08:00 ET

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer

Preclinical data shows that BriaCell's Bria-OTS+ and Bria-PROS+ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, a

GlobeNewswireApr 10 08:00 ET